Greisen, S. R.8; Rasmussen, T. K.8; Stengaard-Pedersen, K.9; Hetland, M. L.6; Horslev-Petersen, K.7; Hvid, M.8; Deleuran, B.8
1 Department of Biomedicine - Institute of Biophysics, Department of Biomedicine, Health, Aarhus University2 Aarhus University Press3 Department of Clinical Medicine - The Section for Rheumatology, Department of Clinical Medicine, Health, Aarhus University4 Department of Biomedicine - Forskning og uddannelse, Øst, Department of Biomedicine, Health, Aarhus University5 Institute of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus University6 Københavns Universitet7 Syddansk universitet8 Department of Biomedicine - Forskning og uddannelse, Øst, Department of Biomedicine, Health, Aarhus University9 Department of Clinical Medicine - The Section for Rheumatology, Department of Clinical Medicine, Health, Aarhus University
OBJECTIVES: Programmed death-1 (PD-1) is an immunoregulatory molecule functioning by down-regulating immune responses. PD-1 is present on follicular helper T cells (TFH) and is important in the formation of plasma cells. PD-1 exists in a bioactive soluble form (sPD-1) and is thought to be implicated in disease activity in chronic rheumatoid arthritis (RA). METHOD: We measured sPD-1 at baseline and 9 months after treatment initiation in plasma from early RA patients (n = 34). We tested for correlations with the Disease Activity Score using 28 joint counts (DAS28), the Health Assessment Questionnaire (HAQ) score, immunoglobulin M rheumatoid factor (IgM-RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, C-reactive protein (CRP), interleukin-21 (IL-21), and total Sharp score (TSS). We also measured sPD-1 in plasma from healthy volunteers (HV) (n = 20) and in plasma and synovial fluid (SF) from patients with chronic RA (> 8 years of disease, n = 30). We further investigated the cellular expression of PD-1 and its ligand PD-L1. RESULTS: sPD-1 concentrations in early [median 0.421 ng/mL, interquartile range (IQR) 0.04-2.560 ng/mL] and chronic (median 0.239 ng/mL, IQR 0.184-0.584 ng/mL) RA were increased compared with HV (median 0.04 ng/mL, IQR 0.04-0.04 ng/mL) (all p < 0.005). In early RA the change in sPD-1 was associated with DAS28 (r = 0.363, p < 0.05) and HAQ score (r = 0.554, p < 0.05) and inversely with TSS at 3-5 years (r = -0.468, p < 0.05). sPD-1 concentration correlated with IgM-RF, anti-CCP antibodies, and IL-21 (all p < 0.05). PD-1 was primarily expressed by synovial memory T cells whereas PD-L1 was mainly expressed by synovial monocytes. CONCLUSIONS: The significantly elevated plasma levels of sPD-1 in early RA, the association with core disease parameters, and the inverse correlation with TSS suggest that sPD-1 is an important mediator in inflammatory and radiographic disease progression.
Scandinavian Journal of Rheumatology, 2014, Vol 43, Issue 2, p. 101-108
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Aged; Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Betamethasone; Biological Markers; Case-Control Studies; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interleukins; Longitudinal Studies; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Programmed Cell Death 1 Receptor; Rheumatoid Factor; Severity of Illness Index